- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03026244
Effect of Milk Protein and Prebiotics in Combination With Vitamin D on Innate Immunity in Elderly People
A Nutritional Intervention Study to Evaluate the Effect of Milk Protein and Prebiotics in Combination With Vitamin D on Innate Immunity in Elderly People
Rationale: The immune system in the ageing population becomes compromised with age (termed "Immunosenescence"). Therefore, elderly people have a decreased ability to respond to infection and vaccination. Furthermore, many of the health issues associated with ageing are linked to inflammation ("Inflammaging"). It has been suggested that this compromised immune function is in part due to reduced Toll-like receptor (TLR) function, which is part of the innate immune system. Milk and dairy based products have been shown to have beneficial effects on inflammation and immunity. This effect may be mediated via support of the innate immune response and promotes TLR7 signaling in in vitro assays (unpublished observation). Also prebiotics have been suggested to influence markers of innate immune function. Furthermore, TLR function has been suggested to be correlated to vitamin D status. Therefore, in the current pilot study, the potential of milk protein, prebiotics and vitamin D to support innate immune function in elderly will be investigated.
Objective: Aim of the current study is to evaluate the effect of milk protein on the innate immune response in elderly in a pilot study. Furthermore, support of this effect by prebiotics and Vitamin D will be studied.
Study design: The study will be a double-blind placebo-controlled pilot study. Study population: Healthy female elderly subjects of 65-85 years of age. Intervention: Period 1: Milk protein or placebo. Period 2: Milk protein + prebiotics or placebo. Period 3: Milk protein + prebiotics + Vitamin D or placebo.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ede, Netherlands, 6718 ZB
- NIZO food research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female
- Age 65-85 years
- BMI 20-30 kg/m2
- Non-smoking
- Generally healthy
- Regular and normal Dutch eating habits
- Veins suitable for cannulation (blood sampling)
- Voluntary participation
- Having given written informed consent
- Willing to comply with study procedures
- Accept use of all encoded data, including publication, and the confidential use and storage of all data for 15 years.
- Accept disclosure of the financial benefit of participation in the study to the authorities concerned
Exclusion Criteria:
- Having chronic inflammatory or autoimmune diseases such as rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease
- Disease of GI tract (including major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, bowel resection, known or suspected gastrointestinal disorders, colon or GI tract cancer), liver, gall bladder, kidneys, thyroid gland
- Immune-compromised
- Use of vitamin supplements containing vitamin D and not willing to discontinue this during the study
- Use of anti-inflammatory drugs (for corticosteroids and NSAIDs : frequency >1 per week)
- Use of immunosuppressive drugs
- Excessive alcohol usage (>3 consumptions/day or >15 consumptions/week)
- Participation in any clinical trial including blood sampling and/or administration of substances within 60 days before inclusion in this study
- Use of hormonal replacement therapy
- Mental status that is incompatible with the proper conduct of the study
- A self-reported milk allergy or sensitivity to dairy ingredients
- Unexplained weight loss or weight gain of > 3 kg in the 3 months prior to pre-study screening
- First and second degree relatives of personnel of NIZO food research or Wageningen University, department of Cell Biology and Immunology or Human Nutrition
- Not having a general practitioner
- Not willing to accept information-transfer concerning participation in the study, or information regarding his health, like laboratory results and eventual adverse events to and from his general practitioner
- Holiday to a sunny country during the study, starting from inclusion
- Light therapy during the study, starting from inclusion
- Use of prebiotic supplements during 2 months before study start, and during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nutritional intervention product
Milk protein, prebiotics, vitamin D
|
3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
|
Placebo Comparator: Placebo product
placebo product
|
3 periods of 3 weeks placebo product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of ex vivo IFN-a production by PBMCs, corrected for baseline
Time Frame: baseline, 3 weeks, 6 weeks, 9 weeks
|
Maximum IFN-a levels after 3, 6 and 9 weeks of treatment as compared to baseline in supernatant of PBMCs ex vivo stimulated with TLR ligands.
|
baseline, 3 weeks, 6 weeks, 9 weeks
|
Cmax of ex vivo IL-6 production by PBMCs, corrected for baseline
Time Frame: baseline, 3 weeks, 6 weeks, 9 weeks
|
Maximum IL-6 levels after 3, 6 and 9 weeks of treatment as compared to baseline in supernatant of PBMCs ex vivo stimulated with TLR ligands.
|
baseline, 3 weeks, 6 weeks, 9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of ex vivo TNF-a production by PBMCs, corrected for baseline
Time Frame: baseline, 3 weeks, 6 weeks, 9 weeks
|
Maximum TNF-a levels after 3, 6 and 9 weeks of treatment as compared to baseline in supernatant of PBMCs ex vivo stimulated with TLR ligands.
|
baseline, 3 weeks, 6 weeks, 9 weeks
|
Change from baseline in percentage IFN-a producing pDCs
Time Frame: baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Percentage IFN-a-producing pDCs in PBMCs upon ex vivo stimulation with TLR ligands determined by flow cytometry
|
baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Change from baseline in percentage IL-6 producing pDCs
Time Frame: baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Percentage IL-6-producing pDCs in PBMCs upon ex vivo stimulation with TLR ligands determined by flow cytometry
|
baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Change from baseline in percentage TNF-a producing pDCs
Time Frame: baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Percentage TNF-a-producing pDCs in PBMCs upon ex vivo stimulation with TLR ligands determined by flow cytometry
|
baseline, and highest percentage at either 3 weeks, 6 weeks, or 9 weeks of treatment
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL57345.081.16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
University of EdinburghUmeå UniversityCompletedSystemic Inflammation | Respiratory InflammationSweden
-
University of AarhusAarhus University Hospital; University of CopenhagenCompletedSystemic Inflammation | Airway InflammationDenmark
-
Sykehuset TelemarkRikshospitalet University Hospital; Helse Sor-OstCompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust ExposureNorway
-
Assistance Publique - Hôpitaux de ParisCompletedDigestive InflammationFrance
-
Pamukkale UniversityCompletedPeriodontal InflammationTurkey
-
Universidade Federal do ParaCompleted
-
KLE Society's Institute of Dental SciencesCompletedRegenerative InflammationIndia
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Oral Science International Inc.AdvarraNot yet recruiting
Clinical Trials on Milk protein, prebiotics, vitamin D
-
Mead Johnson NutritionCompleted
-
Brigham and Women's HospitalCompletedVitamin d Deficiency
-
Danone NutriciaNutricia Early Life Nutrition (Shanghai) Co., LtdCompleted
-
Danone Asia Pacific Holdings Pte, Ltd.National University Hospital, Singapore; Phramongkutklao College of Medicine... and other collaboratorsTerminatedInfantile ColicThailand, Singapore
-
Huazhong University of Science and TechnologyNot yet recruiting
-
University of CopenhagenUniversity of Aarhus; Arla Foods; Arla Foods IngredientsCompletedAppetite Regulation | Muscle Function | Cardiometabolic Health | Bone HealthDenmark
-
Hillel Yaffe Medical CenterTechnion, Israel Institute of TechnologyUnknown
-
Abbott NutritionCompleted
-
Mead Johnson NutritionUniversity of Kansas Medical CenterCompletedBehavioral Measures of ToleranceUnited States
-
ForskningsenhedenUniversity of Copenhagen; Glostrup University Hospital, Copenhagen; The Danish... and other collaboratorsCompleted